MetaVia (NASDAQ:MTVA) Now Covered by Analysts at HC Wainwright

HC Wainwright initiated coverage on shares of MetaVia (NASDAQ:MTVAFree Report) in a research note issued to investors on Monday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $12.00 target price on the stock.

MetaVia Trading Up 12.5 %

Shares of NASDAQ MTVA opened at $1.98 on Monday. MetaVia has a 1 year low of $1.51 and a 1 year high of $6.75.

About MetaVia

(Get Free Report)

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.

Featured Stories

Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.